Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Detection of a SARS-CoV-2 variant of concern in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615

A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice

Coria, L. M., Saposnik, L. M., Castro, C. P., Castro, E. F., Bruno, L. A., Stone, W. B., Pérez, P. S., Darriba, M. L., Chemes, L. B., Alcaín, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844837 · Cited by 20

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2

Pymm, P., Redmond, S. J., Dolezal, O., Mordant, F. L., López, E., Cooney, J. P., Davidson, K. C., Haycroft, E. R., Tan, C. W., Seneviratna, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105259 · Cited by 21

Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants

Moyo-Gwete, T., Madzivhandila, M., Mkhize, N. N., Kgagudi, P., Ayres, F., Lambson, B. E., Manamela, N. P., Richardson, S. I., Makhado, Z., van der Mescht, M. A., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00558-22 · Cited by 18

Designed miniproteins potently inhibit and protect against MERS-CoV

Ragotte, R. J., Tortorici, M. A., Catanzaro, N., Addetia, A., Coventry, B., Froggatt, H. M., Lee, J., Stewart, C., Brown, J. T., Goreshnik, I., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115760 · Cited by 18

Persistence of SARS‐CoV‐2 infection and viral intra ‐ and inter ‐host evolution in COVID‐19 hospitalized patients

Pavia, G., Quirino, A., Marascio, N., Veneziano, C., Longhini, F., Bruni, A., Garofalo, E., Pantanella, M., Manno, M., Gigliotti, S., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29708 · Cited by 18

The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines

Murano, K., Guo, Y., & Siomi, H. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210859 · Cited by 17

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Deliyannis, G., Gherardin, N. A., Wong, C. Y., Grimley, S. L., Cooney, J. P., Redmond, S. J., Ellenberg, P. C., Davidson, K. C., Mordant, F. L., Smith, T., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104574 · Cited by 16

Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern

da Silva, E. S., Servais, J.-Y., Kohnen, M., Arendt, V., Staub, T., Krüger, R., Fagherazzi, G., Wilmes, P., Hübschen, J. M., Ollert, M. W., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914965 · Cited by 17

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster

Nolan, T. M., Deliyannis, G., Griffith, M., Braat, S., Allen, L. F., Audsley, J., Chung, A. W., Ciula, M., Gherardin, N. A., Giles, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104878 · Cited by 16

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV

Chao, C. W., Sprouse, K. R., Miranda, M. C., Catanzaro, N., Hubbard, M. L., Addetia, A., Stewart, C., Brown, J. T., Dosey, A. M., Valdez, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115036 · Cited by 18

A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts

Schultz, M. D., Suschak, J. J., Botta, D., Silva-Sánchez, A., King, R. G., Detchemendy, T. W., Meshram, C. D., Foote, J. B., Zhou, F., Tipper, J. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2127292 · Cited by 16

Evolutionary trajectory of SARS-CoV-2 genome shifts during widespread vaccination and emergence of Omicron variant

Gayvert, K. M., McKay, S., Lim, W. K., Baum, A., Kyratsous, C. A., Copin, R., & Atwal, G. S. (2023) · npj Viruses · doi:10.1038/s44298-023-00007-z · Cited by 17

Molecular characterization of SARS-CoV-2 detected in Tokyo, Japan during five waves: Identification of the amino acid substitutions associated with transmissibility and severity

Tsuchiya, K., Yamamoto, N., Hosaka, Y., Wakita, M., Hiki, M., Matsushita, Y., Mori, H., Hori, S., Misawa, S., Miida, T., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.912061 · Cited by 15

Deep mutagenesis scanning using whole trimeric SARS-CoV-2 spike highlights the importance of NTD-RBD interactions in determining spike phenotype

Kugathasan, R., Sukhova, K., Moshe, M., Kellam, P., & Barclay, W. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011545 · Cited by 16

The atomic portrait of SARS‐CoV‐2 as captured by cryo‐electron microscopy

Fertig, T. E., Chiţoiu, L., Terinte‐Balcan, G., Peteu, V. E., Marta, D. S., & Gherghiceanu, M. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17103 · Cited by 14

Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination

Astakhova, E. A., Byazrova, M. G., Yusubalieva, G. M., Kulemzin, S. V., Kruglova, N. A., Prilipov, A. G., Baklaushev, V. P., Gorchakov, A. A., Taranin, A. V., & Filatov, A. V. (2022) · Cells · doi:10.3390/cells11131991 · Cited by 18

Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants

Changrob, S., Halfmann, P., Liu, H., Torres, J. L., McGrath, J. J. C., Ozorowski, G., Li, L., Wilbanks, G. D., Kuroda, M., Maemura, T., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166844 · Cited by 13

A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses

Torresi, J., Edeling, M. A., Nolan, T. M., & Godfrey, D. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914167 · Cited by 15

The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19

Łysek-Gładysińska, M., Starz, M., Borowiec-Sęk, A., Sufin, I., Wieczorek, A., Chrapek, M., Zarębska‐Michaluk, D., Sufin, P., Głuszek, S., & Adamus-Białek, W. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s394760 · Cited by 17

mRNA-based technology for engineered regenerative medicine

Zhen, X., Chen, W., & Tao, W. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100185 · Cited by 16

Mosaic vaccination: How distributing different vaccines across a population could improve epidemic control

McLeod, D. V., Wahl, L. M., & Mideo, N. (2021) · Evolution Letters · doi:10.1002/evl3.252 · Cited by 14

Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination

Datta, P., Ukey, R., Bruiners, N., Honnen, W. J., Carayannopoulos, M. O., Reichman, C., Choudhary, A. K., Onyuka, A., Handler, D., Guerrini, V., et al. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113165 · Cited by 13

Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic

Kapten, K., Orczyk, K., & Smolewska, E. B. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00673-0 · Cited by 12

Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination

Graninger, M., Camp, J. V., Aberle, S. W., Traugott, M. T., Hoepler, W., Puchhammer‐Stöckl, E., Weseslindtner, L., Zoufaly, A., Aberle, J. H., & Stiasny, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888794 · Cited by 12

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

Leal, L., Pich, J., Ferrer, L., Nava, J., Martí‐Lluch, R., Esteban, I., Pradenas, E., Regué, D. R., Prenafeta, A., Escobar, K., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00736-5 · Cited by 13

Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand

Tandhavanant, S., Koosakunirand, S., Kaewarpai, T., Piyaphanee, W., Leaungwutiwong, P., Luvira, V., & Chantratita, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255796 · Cited by 11

Getting to the (germinal) center of humoral immune responses to SARS-CoV-2

Tangye, S. G., Burnett, D. L., & Bull, R. A. (2022) · Cell · doi:10.1016/j.cell.2022.02.018 · Cited by 11

Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motifPreprint

Hauser, B. M., Sangesland, M., Lam, E. C., Denis, K. S., Feldman, J. E., Yousif, A. S., Caradonna, T. M., Kannegieter, T., Balazs, A. B., Lingwood, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.07.415216 · Cited by 11

Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variantPreprint

Ikemura, N., Taminishi, S., Inaba, T., Arimori, T., Motooka, D., Katoh, K., Kirita, Y., Higuchi, Y., Li, S., Suzuki, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.22.473804 · Cited by 11

Persistent immune imprinting after XBB.1.5 COVID vaccination in humansPreprint

Tortorici, M. A., Addetia, A., Seo, A. J., Brown, J. T., Sprouse, K. R., Logue, J., Clark, E., Franko, N., Chu, H. Y., & Veesler, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.28.569129 · Cited by 11

Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses

Rexhepaj, M., Asarnow, D. E., Perruzza, L., Park, Y., Guarino, B., Mccallum, M., Culap, K., Saliba, C., Leoni, G., Balmelli, A., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.10.001 · Cited by 10

SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals

Dadonaite, B., Burrell, A. R., Logue, J., Chu, H. Y., Payne, D. C., Haslam, D. B., Staat, M. A., & Bloom, J. D. (2025) · Journal of Virology · doi:10.1128/jvi.00109-25 · Cited by 10

SpikePro: a webserver to predict the fitness of SARS-CoV-2 variants

Cia, G., Kwasigroch, J. M., Rooman, M. J., & Pucci, F. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac517 · Cited by 10

Comprehensive profiling of neutralizing polyclonal sera targeting coxsackievirus B3

Álvarez‐Rodríguez, B., Buceta, J., & Geller, R. (2023) · Nature Communications · doi:10.1038/s41467-023-42144-2 · Cited by 10

Development of an RBD-Fc fusion vaccine for COVID-19

Sun, Y., Li, Q., Luo, Y., Zhu, H., Fang, X., Lu, H.-J., Yao, P., Wang, Z., Zhao, W., & Zhou, Z. M. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100444 · Cited by 10

Early detection of emerging SARS-CoV-2 variants of interest for experimental evaluation

Wallace, Z. S., Davis, J. J., Niewiadomska, A. M., Olson, R., Shukla, M. P., Stevens, R. L., Zhang, Y., Zmasek, C. M., & Scheuermann, R. H. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.1020189 · Cited by 8

The speed of vaccination rollout and the risk of pathogen adaptation

Gandon, S., Lambert, A., Voinson, M., Day, T., & Parsons, T. L. (2025) · Journal of The Royal Society Interface · doi:10.1098/rsif.2025.0060 · Cited by 7

Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine–Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019

Tang, J., Grubbs, G., Lee, Y., Wu, H., Luke, T. C., Egland, K. A., Bausch, C. L., Sullivan, E. J., & Khurana, S. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac031 · Cited by 9

Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations

Cia, G., Pucci, F., & Rooman, M. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042078 · Cited by 9

mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity Against SARS-CoV-2

Noor, R. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01168-3 · Cited by 9

The identification of polyvalent protective immunogens and immune abilities from the outer membrane proteins of Aeromonas hydrophila in fish

Liu, X., Rong, N., Sun, W., Jian, S., Chao, J., Chen, C., Chen, R., Ding, R., Chen, C., Liu, Y., et al. (2022) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2022.07.057 · Cited by 9

Spike mutations that affect the function and antigenicity of recent KP.3.1.1-like SARS-CoV-2 variants

Dadonaite, B., Harari, S., Larsen, B. B., Kampman, L., Harteloo, A., Elias-Warren, A., Chu, H. Y., & Bloom, J. D. (2025) · Journal of Virology · doi:10.1128/jvi.01423-25 · Cited by 11

Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques

Willcox, A. C., Sung, K., Garrett, M. E., Galloway, J., O’Connor, M. A., Erasmus, J. H., Logue, J. K., Hawman, D. W., Chu, H. Y., Hasenkrug, K. J., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010155 · Cited by 9

Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern

Sun, P., Ramos, I., Coelho, C. H., Grifoni, A., Balinsky, C. A., Vangeti, S., Tarke, A., Bloom, N. I., Jani, V., Jakubski, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105202 · Cited by 7

A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti‐spike antibodies according to SARS‐CoV‐2 vaccination and infections status

Camacho, J., Albert, E., Zulaica, J., Álvarez‐Rodríguez, B., Rusu, L., Olea, B., Alcaráz, M. J., Geller, R., Giménez, E., & Navarro, D. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28397 · Cited by 7

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

Kaabi, N. A., Yang, Y. K., Liang, Y., Xu, K., Zhang, X. F., Kang, Y., Jin, Y. Q., Hou, J. W., Zhang, J., Yang, T., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01295-2 · Cited by 10

Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated personsPreprint

Tzou, P. L., Tao, K., Pond, S. L. K., & Shafer, R. W. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.24.469823 · Cited by 8

Evolution of SARS-CoV-2 during the first year of the COVID-19 pandemic in Northwestern Argentina

Montaño, R. Z., Culasso, A. C. A., Fernández, F. D., Marquez, N., Debat, H., Salmerón, M., Zamora, A. M., de Huidobro, G. R., Costas, D., Alabarse, G., et al. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198936 · Cited by 8

Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design

Hauser, B. M., Feldman, J. E., Sangesland, M., Ronsard, L., Denis, K. S., Sheehan, M. L., Cao, Y., Boucau, J., Windsor, I. W., Cheng, A. H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100834 · Cited by 6

Comparison of Physicochemical Properties of LipoParticles as mRNA Carrier Prepared by Automated Microfluidic System and Bulk Method

Ayad, C., Yavuz, A., Salvi, J.-P., Libeau, P., Exposito, J., Ginet, V., Monge, C., Verrier, B., & Arruda, D. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061297 · Cited by 7

The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity

Liu, H., Wei, P., Zhang, Q., Aviszus, K., Linderberger, J., Yang, J. J., Liu, J., Chen, Z., Waheed, H., Reynoso, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911325 · Cited by 39

Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial

Isa, F., Ortiz, A. M. G., Meyer, J., Hamilton, J. D., Olenchock, B. A., Brackin, T., Ganguly, S., Forleo‐Neto, E., Faria, L., Heirman, I., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00421-3 · Cited by 7

What next for covid-19 vaccines?: Video 1

Looi, M.-K., & Mahase, E. (2022) · BMJ · doi:10.1136/bmj.o2422 · Cited by 7

Immunogenicity of COVID-19 mRNA Vaccines in Immunocompromised Patients: A Systematic Review and Meta-AnalysisPreprint

Mehrabinejad, M.-M., Moosaie, F., Dehghanbanadaki, H., Ghadery, A. H., Shabani, M., Tabary, M., Aryannejad, A., SeyedAlinaghi, S., & Rezaei, N. (2021) · Research Square · doi:10.21203/rs.3.rs-994503/v1 · Cited by 7

Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans

Tortorici, M. A., Sprouse, K. R., Addetia, A., Brown, J. T., Lee, J., Stewart, C., Merz, B., Harteloo, A., Elias-Warren, A., Chu, H. Y., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117052 · Cited by 8

Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein

Pérez-Massón, B., Quintana-Perez, Y., Tundidor, Y., Pérez‐Martínez, D., Castro-Martínez, C., Pupo-Meriño, M., Orosa-Vázquez, I., Relova-Hernández, E., Villegas, R., Guirola, O., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-50450-4 · Cited by 6

Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting

Seow, J., Jefferson, G. C. E., Keegan, M. D., Yau, Y., Snell, L. B., & Doores, K. J. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012724 · Cited by 6

Interaction of HERVs with PAMPs in Dysregulation of Immune Response Cascade Upon SARS-CoV-2 Infections

Turčić, M., Pavelić, S. K., Trivanović, D., & Pavelić, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413360 · Cited by 8

Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

Wang, Y., Gao, T., Li, W., Tai, C., Xie, Y., Chen, D., Liu, S., Huang, F., Wang, W., Chen, Y., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01099-z · Cited by 6

A recurring YYDRxG pattern in broadly neutralizing antibodies to a conserved site on SARS-CoV-2, variants of concern, and related virusesPreprint

Liu, H., Kaku, C. I., Song, G., Yuan, M., Andrabi, R., Burton, D. R., Walker, L. M., & Wilson, I. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.15.472864 · Cited by 6

Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls

Karaba, A. H., Morgenlander, W. R., Johnston, T. S., Hage, C., Pekosz, A. S., Durand, C. M., Segev, D. L., Robien, M. A., Heeger, P. S., Larsen, C. P., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad534 · Cited by 5

Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines

Bangaru, S., Jackson, A. M., Copps, J., Fernández‐Quintero, M. L., Torres, J. L., Richey, S. T., Nogal, B., Sewall, L. M., de la Peña, A. T., Rehman, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115986 · Cited by 6

The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2

Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5

Longitudinal Neutralization Activities on Authentic Omicron Variant Provided by 3 Doses of BBIBP-CorV Vaccination During One Year

Lai, D., Xue, J., He, P., Jiang, H., Yang, L., Ma, M., Hong, W., Yu, J., Wei, H., & Tao, S. (2022) · PROTEOMICS · doi:10.1002/pmic.202200306 · Cited by 4

Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection

Pidal, P., Fernández, J. O., Airola, C., Araujo, M., Menjiba, A. M., Martín, H. S., Bruneau, N., Balanda, M., Elgueta, C., Fasce, R., et al. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00753-6 · Cited by 5

Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus

Papaneophytou, C. P., Nicolaou, A., Pieri, M., Nicolaidou, V., Galatou, E., Sarigiannis, Y. M., Pantelidou, M., Panayi, P., Thoma, T., Stavraki, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269885 · Cited by 6

B Cell Receptor Repertoire Kinetics after SARS-CoV-2 Infection and VaccinationPreprint

Kotagiri, P., Mescia, F., Rae, W. M., Bergamaschi, L., Tuong, Z. K., Turner, L., Hunter, K., Gerber, F. P. P., Hosmillo, M. D. T., Hess, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3910805 · Cited by 5

Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variantsPreprint

Jiang, N., Wang, L., Hatta, M., Feng, C., Currier, M., Lin, X., Hossain, J., Cui, D., Mann, B. R., Kovacs, N. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.08.523127 · Cited by 5

Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article

El‐Baky, N. A., & Amara, A. A. A. F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.903876 · Cited by 5

Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections

Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Lau, B., Liang, C.-Y., Burgess, J. L., Ellingson, K., Beitel, S. C., Romine, J. K., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02162-2 · Cited by 5

A novel nanoparticle vaccine, based on S1-CTD, elicits robust protective immune responses against porcine deltacoronavirus

He, Q., Zou, Y., Yu, B., Yuan, Q., Meng, C., Du, C., Wang, Z., Lian, J., Luo, S., Cao, S., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00674-25 · Cited by 4

Epitope mapping of SARS-CoV-2 spike protein differentiates the antibody binding activity in vaccinated and infected individuals

Felbinger, N. R., Trudil, D., Loomis, L. D., Ascione, R., Siragusa, G. R., Haba, S., Rastogi, S., Mucci, A., Claycomb, M., Snowberger, S., et al. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.988109 · Cited by 4

Impact of prior SARS-COV-2 infection and vaccination on COVID-19 hospital admission and mortality amongst nursing home residents

España, P. P., Bilbao‐González, A., Larrea, N., Castillo-Sintes, I., García‐Gutiérrez, S., Portuondo, J., Villanueva, A., Uranga, A., Legarreta, M. J., Gascón, M., et al. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02446-3 · Cited by 5

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variantsPreprint

Du, W., Hurdiss, D. L., Drabek, D., Mykytyn, A. Z., Kaiser, F. K., González-Hernández, M. C., Muñoz‐Santos, D., Lamers, M. M., van Haperen, R., Li, W., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.17.480751 · Cited by 4

mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures

Cohen, A. A., Keeffe, J. R., Manasyan, L., Madireddy, I., Fils, A.-C. I. P., Dam, K.-M. A., Stober, H. E., Hills, R. A., Moon, W. J., Lin, P. J. C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117335 · Cited by 4

Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19

Cha, H. H., Lim, S. Y., Kwon, J., Kim, J. Y., Bae, S., Jung, J., & Kim, S. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.409 · Cited by 3

Adenovirus Vaccine Containing Truncated SARS-CoV-2 Spike Protein S1 Subunit Leads to a Specific Immune Response in Mice

Chen, K., Shi, D., Li, C., Fang, Z., Guo, Y., Jiang, W., Li, J., Li, H., & Yao, H. (2023) · Vaccines · doi:10.3390/vaccines11020429 · Cited by 3

The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model

Dickson, A. M., Geerling, E., Stone, E. T., Hassert, M., Steffen, T. L., Makkena, T., Smither, M., Schwetye, K. E., Zhang, J., Georges, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188392 · Cited by 3

The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine

Chen, X., Mohapatra, A., Nguyen, H. T. V., Schimanski, L. M., Tan, T. K., Rijal, P., Chen, C., Cheng, S., Lee, W.-H., Chou, Y., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012246 · Cited by 3

Which test results to believe? Comparison of different ELISA kits for detection of SARS-CoV-2-neutralizing antibody among COVID-vaccinated individuals

Yanamandra, U., Tandel, K., Rayapureddi, K., Singh, S. P., Arivalagan, B., Kalra, D. K., Sahu, R., Menon, A. S., & Kotwal, N. (2024) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2024.05.014 · Cited by 3

COVID-19 and the Unraveling of Experimental Medicine - Part II

Thorp, K. E., & Thorp, J. A. (2022) · The Gazette of Medical Sciences · doi:10.46766/thegms.pubheal.22022804 · Cited by 3

Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors

Lu, B., Zhu, K.-L., Cui, X.-M., Lin, Y., Wang, X., Wang, G., Duan, L., Qian, A., & Ma, M. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109103 · Cited by 3

A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response

Campbell, E., Dobkin, J., Osorio, L., Kolloli, A., Ramasamy, S., Kumar, R., Sant’Angelo, D. B., Subbian, S., Denzin, L. K., & Anderson, S. (2023) · Vaccines · doi:10.3390/vaccines11040832 · Cited by 3

Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study

Alfonso, R., Lin, J., Lei, J., Liu, J., Roche, M., Oliveira, A. D., Raisingani, A., Kumar, A., Kirschner, V., Feuer, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1194671 · Cited by 3

Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trialPreprint

Leal, L., Pich, J., Ferrer, L., Nava, J., Martí‐Lluch, R., Esteban, I., Pradenas, E., Regué, D. R., Prenafeta, A., Escobar, K., et al. (2022) · medRxiv · doi:10.1101/2022.08.09.22278560 · Cited by 3

Characterization of SARS-CoV-2 Convalescent Patients’ Serological Repertoire Reveals High Prevalence of Iso–RBD AntibodiesPreprint

Curtis, N. C., Shin, S., Hederman, A. P., Connor, R. I., Wieland‐Alter, W., Ionov, S., Boylston, J. A., Rose, J., Sakharkar, M., Dorman, D. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.08.556349 · Cited by 4

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccinesPreprint

Lee, J., Stewart, C., Schaefer, A., Leaf, E. M., Park, Y., Asarnow, D. E., Powers, J. M., Treichel, C., Corti, D., Baric, R. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.12.571160 · Cited by 3

A novel platform for engineered AAV-based vaccines

Babutzka, S., Gehrke, M., Παπαδοπούλου, Α., Diedrichs‐Möhring, M., Giannaki, M., Hennis, L., Föhr, B., Kooyman, C., Osterman, A., Yannaki, E., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101418 · Cited by 2

The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution

Wu, C.-Y., Yang, Y.-H., Lin, Y.-S., Shu, L.-H., Cheng, Y.-C., Liu, H.-T., Lin, Y., Lee, I.-Y., Shih, W.-T., Yang, P.-R., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17701 · Cited by 2

Rethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination

Blanco, J., Trinité, B., & Puig‐Barberà, J. (2025) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70076 · Cited by 2

Stabilizing Prefusion SARS-CoV-2 Spike by Destabilizing the Postfusion Conformation

Chakraborty, D., Singh, R., Rajmani, R. S., Kumar, S., Ringe, R. P., & Varadarajan, R. (2025) · Vaccines · doi:10.3390/vaccines13030315 · Cited by 2

Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review

Gutlapalli, S. D., Ganipineni, V. D. P., Danda, S., Fabián, D., Okorie, I. J., Paramsothy, J., Kailayanathan, T., Umyarova, R., Aviles, C., Garlapati, S. K. P., et al. (2023) · Cureus · doi:10.7759/cureus.36809 · Cited by 2

Identification of an Optimized Receptor-Binding Domain Subunit Vaccine against SARS-CoV-2

Yu, H. B., Worrall, L. J., Berger, T., Petric, M., Lin, B. H., Vuckovic, M., Robb, C. S., Le, Q., Kenward, C., Dai, C., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300282 · Cited by 2

SARS-CoV-2 Immunity: Review of Immune Response to Infection and Vaccination

Ahmad, R. (2021) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v20i5.55398 · Cited by 2

A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infectionPreprint

Coria, L. M., Saposnik, L. M., Castro, C. P., Castro, E. F., Bruno, L. A., Stone, W. B., Pérez, P. S., Darriba, M. L., Chemes, L. B., Alcaín, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.07.471590 · Cited by 2

Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4 th Dose BoosterPreprint

Nolan, T. M., Deliyannis, G., Griffith, M., Braat, S., Allen, L. F., Audsley, J., Chung, A. W., Ciula, M., Gherardin, N. A., Giles, M., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4485603 · Cited by 2

Deep mutational scanning of whole SARS-CoV-2 spike in an inverted infection systemPreprint

Taminishi, S., Li, S., Higuchi, Y., Kirita, Y., Motooka, D., Ozaki, Y., Arimori, T., Ikemura, N., Itoh, Y., Matoba, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.17.549430 · Cited by 2

Predicting SARS-CoV-2 evolution dynamics with spatiotemporal resolution by DMS-empowered protein language modelPreprint

Yang, S., Luo, X., Luo, J., Jian, F., & Cao, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.683094 · Cited by 2

Molecular basis of pathogenicity of the recently emerged FCoV-23 coronavirusPreprint

Tortorici, M. A., Choi, A., Gibson, C. A., Lee, J., Brown, J. T., Stewart, C., Joshi, A., Harari, S., Willoughby, I., Treichel, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.25.607996 · Cited by 2

Viral immunity: Basic mechanisms and therapeutic applications—a Keystone Symposia report

Cable, J., Balachandran, S., Daley‐Bauer, L. P., Rustagi, A., Antony, F., Frere, J. J., Strampe, J., Kedzierska, K., Cannon, J. L., McGargill, M. A., et al. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14960 · Cited by 1

Defining the Antigenic Topology and Prospective Binding Breadth of Vaccination-induced SARS-CoV-2 Neutralizing AntibodiesPreprint

Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.03.709398

High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients

Nitahara, Y., Nakagama, Y., Kaku, N., Candray, K., Michimuko, Y., Tshibangu-Kabamba, E., Kaneko, A., Yamamoto, H., Mizobata, Y., Kakeya, H., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00965-21 · Cited by 25

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Cho, A., Muecksch, F., Schaefer-Babajew, D. J., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · Nature · doi:10.1038/s41586-021-04060-7 · Cited by 263

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsPreprint

Pegu, A., O’Connell, S. E., Schmidt, S. D., O'Dell, S. J., Talana, C. A., Lai, L., Albert, J., Anderson, E. J., Bennett, H., Corbett, K. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.13.444010 · Cited by 50